$8.61
0.69% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US0050831009
Symbol
ACTU
Sector
Industry

Actuate Therapeutics Stock price

$8.61
-1.84 17.61% 1M
+0.32 3.86% 6M
+0.65 8.17% YTD
+0.61 7.63% 1Y
+0.61 7.63% 5Y
+0.61 7.63% 10Y
+0.61 7.63% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.06 0.69%
ISIN
US0050831009
Symbol
ACTU
Sector
Industry

Key metrics

Market capitalization $168.93m
Enterprise Value $165.45m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-23.41m
Free Cash Flow (TTM) Free Cash Flow $-21.21m
Cash position $3.89m
EPS (TTM) EPS $-1.28
P/E forward negative
Short interest 3.47%
Show more

Is Actuate Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Actuate Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Actuate Therapeutics forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Actuate Therapeutics forecast:

Buy
100%

Financial data from Actuate Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.72 8.72
-
-
- Research and Development Expense 15 15
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -23 -23
-
-
Net Profit -25 -25
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Actuate Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Actuate Therapeutics Stock News

Neutral
GlobeNewsWire
13 days ago
CHICAGO and FORT WORTH, Texas, May 31, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today presented topline results from the Phase 2 (Actuate...
Neutral
GlobeNewsWire
22 days ago
CHICAGO and FORT WORTH, Texas, May 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the online publication of the abstract ac...
Neutral
GlobeNewsWire
about 2 months ago
- Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)
More Actuate Therapeutics News

Company Profile

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Head office United States
CEO Daniel Schmitt
Website actuatetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today